Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP & Chief Financial Officer | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,362 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 928 · Balance 78,362 F1: Includes 500 shares acquired under the Issuer's stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 79,056 |
Reported balance
After 2026-09-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-02 · Exercise / conversion · Acquired 694 · Balance 79,056 |
| Common StockSEC Table I · non-derivative | Direct | 79,676 |
Reported balance
After 2026-09-02 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-02 · Exercise / conversion · Acquired 620 · Balance 79,676 |
| Common StockSEC Table I · non-derivative | Direct | 81,676 |
Reported balance
After 2026-09-02 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-02 · Exercise / conversion · Acquired 2,000 · Balance 81,676 F2: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 82,962 |
Reported balance
After 2026-09-02 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-02 · Exercise / conversion · Acquired 1,286 · Balance 82,962 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.70 · Expires 2034-01-23 | Direct | 12,824 |
Reported balance
After 2026-09-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-02 · Exercise / conversion · Disposed 694 · Balance 12,824 F3: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.70 · Expires 2033-01-26 | Direct | 9,012 |
Reported balance
After 2026-09-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-02 · Exercise / conversion · Disposed 620 · Balance 9,012 F4: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.20 · Expires 2032-01-24 | Direct | 7,999 |
Reported balance
After 2026-09-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-02 · Exercise / conversion · Disposed 2,000 · Balance 7,999 F2: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F5: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.20 · Expires 2030-02-06 | Direct | 15,867 |
Reported balance
After 2026-09-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-02 · Exercise / conversion · Disposed 1,286 · Balance 15,867 F6: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 500 shares acquired under the Issuer's stock purchase plan.
F2: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F3: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period.
F4: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.
F5: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period.
F6: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,286 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · derivative · entry 9 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,867 Underlying: Common Stock · 1,286 shares Expires 2030-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · derivative · entry 8 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,999 Underlying: Common Stock · 2,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F5 · derivative.exercise_date: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period. F2 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 620 | $0.00 Strike: $18.70 | $0.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · derivative · entry 7 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,012 Underlying: Common Stock · 620 shares Expires 2033-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · derivative · entry 6 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,824 Underlying: Common Stock · 694 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 1,286 | $24.20 | $31,121.20 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 5 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 2,000 | $24.20 | $48,400.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 4 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 620 | $18.70 | $11,594.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 3 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 694 | $12.70 | $8,813.80 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 928 | $47.50 | $44,080.00 |
DisclosureSEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,362 F1 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,394 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-26-003036 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 7,394 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,181 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000905148-26-002811 · form4.xml · derivative · entry 5 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,518 Underlying: Common Stock · 2,181 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $18.70 | $0.00 |
DisclosureSEC source: 0000905148-26-002811 · form4.xml · derivative · entry 4 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Underlying: Common Stock · 1,200 shares Expires 2033-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 928 | $29.86 | $27,710.08 |
DisclosureSEC source: 0000905148-26-002811 · form4.xml · nonDerivative · entry 3 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,790 Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 2,181 | $12.70 | $27,698.70 |
DisclosureSEC source: 0000905148-26-002811 · form4.xml · nonDerivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 1,200 | $18.70 | $22,440.00 |
DisclosureSEC source: 0000905148-26-002811 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 20,636 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000952 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,337 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 3,546 | $34.62 | $122,762.52 |
DisclosureSEC source: 0000905148-26-000678 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,701 Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:21 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 5,488 | $36.01 | $197,622.88 |
DisclosureSEC source: 0000905148-26-000497 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,247 F1 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $18.70 | $0.00 |
DisclosureSEC source: 0000905148-25-004492 · form4.xml · derivative · entry 6 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,832 Underlying: Common Stock · 1,667 shares Expires 2033-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F5 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,846 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0000905148-25-004492 · form4.xml · derivative · entry 5 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 2,846 shares Expires 2030-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F4 · derivative.exercise_date: The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,987 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000905148-25-004492 · form4.xml · derivative · entry 4 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,262 Underlying: Common Stock · 1,987 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F3 · derivative.exercise_date: The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 1,667 | $18.70 | $31,172.90 |
DisclosureSEC source: 0000905148-25-004492 · form4.xml · nonDerivative · entry 3 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 2,846 | $24.20 | $68,873.20 |
DisclosureSEC source: 0000905148-25-004492 · form4.xml · nonDerivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 1,987 | $20.00 | $39,740.00 |
DisclosureSEC source: 0000905148-25-004492 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · balance_after: Includes 500 shares of common stock acquired under the Issuer's stock purchase plan. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,394 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-003351 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,394 Underlying: Common Stock · 7,394 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:56 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 7,850 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000905148-25-000980 · form4.xml · derivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires 2034-01-23 F3 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F3 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F3 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:56 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 5,625 | $0.00 Strike: $35.40 | $0.00 |
DisclosureSEC source: 0000905148-25-000980 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2031-01-27 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 5,625 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 01:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 1,734 | $21.93 | $38,019.68 |
DisclosureSEC source: 0000905148-25-000413 · form4.xml · nonDerivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,235 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 2,036 | $20.92 | $42,595.16 |
DisclosureSEC source: 0000905148-25-000413 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,969 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,788 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-000300 · form4.xml · derivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,788 Underlying: Common Stock · 14,788 shares Expires 2035-01-29 F4 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 19,717 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000300 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,005 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026. F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F3 · balance_after: Includes 999 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 01:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $18.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003281 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2033-01-26 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 6,250 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 00:33 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0000905148-24-002511 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-06 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on August 30, 2024, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 10,000 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:16 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 78,500 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000905148-24-000851 · form4.xml · derivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,500 Underlying: Common Stock · 78,500 shares Expires 2034-01-23 F2 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 78,500 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. F3 · derivative.exercise_date: The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:16 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000905148-24-000851 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-01-26 F1 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 62,500 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. F3 · derivative.exercise_date: The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:18 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 7,027 | $1.14 | $8,010.78 |
DisclosureSEC source: 0000905148-24-000446 · form4.xml · nonDerivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,891 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:18 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 5,601 | $1.13 | $6,326.89 |
DisclosureSEC source: 0000905148-24-000446 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,918 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $1.1228 to $1.13. Upon request, the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission staff, full information regarding the shares sold at each such separate price. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:16 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 157,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000905148-24-000306 · form4.xml · derivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,000 Underlying: Common Stock · 157,000 shares Expires 2034-01-23 F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:16 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 209,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000306 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,519 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 1, 2024, with the first annual vest occurring on February 1, 2025. F2 · balance_after: Includes 10,000 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 22:40 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 5,389 | $1.66 | $8,946.28 |
DisclosureSEC source: 0001140361-23-004732 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,519 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001140361-23-003441 · form4.xml · derivative · entry 3 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-01-26 F5 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001140361-23-003441 · form4.xml · derivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-24 F3 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met. F4 · derivative.exercise_date: The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003441 · form4.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,908 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024. F2 · balance_after: Includes 10,000 shares acquired under the issuer's stock purchase plan. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001140361-22-047668 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-24 F1 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On December 28, 2022, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on December 28, 2022, the date the determination was made that the performance metric had been met. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:15 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 81,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-22-033611 · form4.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires 2029-01-23 F1 · shares: The reporting person was granted an option with a performance-based condition with respect to 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 01:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001567619-22-001782 · doc1.xml · derivative · entry 2 Schorno Dean L · CIK 0001509688 · EVP &Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-24 F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 01:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-001782 · doc1.xml · nonDerivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP &Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,908 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023. F2 · balance_after: Includes 28,908 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 23:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 81,250 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001567619-21-019430 · doc1.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 81,250 shares Expires 2029-01-23 F1 · shares: The reporting person was granted a performance-based option to purchase 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on October 25, 2021, the date the performance metric had been met. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:23 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-21-004127 · edgar.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP &Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-06 F1 · shares: The reporting person was granted a performance-based option to purchase 50,000 shares of common stock on February 6, 2020. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On April 1, 2021, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on April 1, 2021, the date the performance metric had been met. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 23:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option(right to buy) · Derivative | 112,500 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001179110-21-000984 · edgar.xml · derivative · entry 1 Schorno Dean L · CIK 0001509688 · EVP &Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2021, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.